Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Cited by (1,002)

Items 101–200 of 1,002

1. Left ventricular remodeling response to SGLT2 inhibitors in heart failure: an updated meta-analysis of randomized controlled studies
   Erberto Carluccio, Paolo Biagioli, Gianpaolo Reboldi, Anna Mengoni, Rosanna Lauciello, Cinzia Zuchi, Sandra D’Addario, Giuliana Bardelli, Giuseppe Ambrosio · 2023 · Cardiovascular Diabetology
2. 2025 ACC Scientific Statement on the Management of Obesity in Adults With Heart Failure
   Kittleson, Michelle M., Benjamin, Emelia J., Blumer, Vanessa, Harrington, Josephine, Januzzi, James L., McMurray, John J.V., Vest, Amanda R. · 2025 · JACC
3. Implications of Atrial Fibrillation for Guideline-Directed Therapy in Patients With Heart Failure
   Joshua D. Newman, Eileen O’Meara, Michael Böhm, Gianluigi Savarese, Patricia R. Kelly, Orly Vardeny, Larry A. Allen, Patrizio Lancellotti, Stephen S. Gottlieb, Zainab Z. Samad et al. · 2024 · Journal of the American College of Cardiology
4. Contemporary pharmacological treatment and management of heart failure
   Biykem Bozkurt · 2024 · Nature Reviews Cardiology
5. SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria
   Brendon Lange Neuen, Robert A. Fletcher, Stefan D. Anker, Deepak L. Bhatt, Javed Butler, David Z.I. Cherney, Kieran F. Docherty, Silvio E. Inzucchi, Meg Jardine, Kenneth W. Mahaffey et al. · 2025 · JAMA
6. How to Manage Heart Failure With Preserved Ejection Fraction
   Akshay Suvas Desai, Carolyn S.P. Lam, John J.V. McMurray, Margaret M. Redfield · 2023 · JACC Heart Failure
7. Predicting and preventing heart failure in type 2 diabetes
   Ambarish Pandey, Muhammad Shahzeb Khan, Kershaw V. Patel, Deepak L. Bhatt, Subodh Verma · 2023 · The Lancet Diabetes & Endocrinology
8. Advances in the management of type 2 diabetes in adults
   Rodolfo Javier Galindo, Jennifer M. Trujillo, Cecilia C. Low Wang, Rozalina G. McCoy · 2023 · BMJ Medicine
9. Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes
   Alexander Kutz, Dae Hyun Kim, Deborah J. Wexler, Jun Liu, Sebastian Schneeweiß, Robert J. Glynn, Elisabetta Patorno · 2023 · Diabetes Care
10. Sex difference in human diseases: mechanistic insights and clinical implications
    Yuncong Shi, Jianshuai Ma, Sijin Li, Chao Liu, Yuning Liu, Jie Chen, Ningning Liu, Shiming Liu, Hui Huang · 2024 · Signal Transduction and Targeted Therapy
11. The impact of the stress hyperglycemia ratio on mortality and rehospitalization rate in patients with acute decompensated heart failure and diabetes
    Qing Zhou, Jie Yang, Wenyao Wang, Chunli Shao, Xinwei Hua, Yida Tang · 2023 · Cardiovascular Diabetology
12. Causal inference in health and disease: a review of the principles and applications of Mendelian randomization
    Catherine Elizabeth Lovegrove, Sarah Howles, Dominic Furniss, Michael Vaclav Holmes · 2024 · Journal of Bone and Mineral Research
13. The Japanese Society of Hypertension Guidelines for the management of elevated blood pressure and hypertension 2025 (JSH2025)
    Yusuke Ohya, Kimika Arakawa, Naoko Arata, Shuji Arima, Hisatomi Arima, K. Asayama, Yasuaki Dohi, Ako Fukami, Masato Furuhashi, Kenichi Goto et al. · 2026 · Hypertension Research
14. Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity
    Zile, Michael R., Borlaug, Barry A., Kramer, Christopher M., Baum, Seth J., Litwin, Sheldon E., Menon, Venu, Ou, Yang, Weerakkody, Govinda J., Hurt, Karla C., Kanu, Chisom et al. · 2025 · Circulation
15. Endothelial cell metabolism in cardiovascular physiology and disease
    Pasut, Alessandra, Lama, Eleonora, Van Craenenbroeck, Amaryllis H., Kroon, Jeffrey, Carmeliet, Peter · 2025 · Nature Reviews Cardiology
16. Sex differences in heart failure with preserved ejection fraction: From traditional risk factors to sex-specific risk factors
    Gurleen Kaur, Emily S. Lau · 2022 · Women s Health
17. Functional and Clinical Importance of SGLT2-inhibitors in Frailty: From the Kidney to the Heart
    Gaetano Santulli, Fahimeh Varzideh, Imma Forzano, Scott Maxwell Wilson, Luigi Salemme, Antonio De Donato, Angela Lombardi, Antonio Rainone, Luigi Nunziata, Stanislovas S. Jankauskas et al. · 2023 · Hypertension
18. UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease 2023 UPDATE
    Alistair Roddick, Alexa Wonnacott, David R. Webb, Angela Watt, Michael A. Watson, Natalie Staplin, Alex Riding, Eirini Lioudaki, Apexa Kuverji, Mohsen El Kossi et al. · 2023 · BMC Nephrology
19. SGLT2 Inhibitors, Functional Capacity, and Quality of Life in Patients With Heart Failure
    Michael Gao, Kirtipal Bhatia, Arjun B. Kapoor, Juan J. Badimón, Sean Pinney, DONNA M. MANCINI, Carlos G. Santos‐Gallego, Anuradha Lala · 2024 · JAMA Network Open
20. Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction
    Muthiah Vaduganathan, Brian Lee Claggett, Pardeep S. Jhund, Rudolf A. de Boer, Adrian F. Hernandez, Silvio E. Inzucchi, Mikhail Kosiborod, Carolyn S.P. Lam, Felipe A. Martínez, Sanjiv Jayendra Shah et al. · 2022 · JAMA Cardiology
21. Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial
    Orly Vardeny, James Chen-Tson Fang, Akshay Suvas Desai, Pardeep S. Jhund, Brian Lee Claggett, Muthiah Vaduganathan, Rudolf A. de Boer, Adrian F. Hernandez, Carolyn S.P. Lam, Silvio E. Inzucchi et al. · 2022 · Nature Medicine
22. Use of Patient-Reported Outcomes in Heart Failure: From Clinical Trials to Routine Practice
    Gianluigi Savarese, JoAnn M. Lindenfeld, Davide Stolfo, Kirkwood F. Adams, Tariq Ahmad, Nihar R. Desai, Enrico Ammirati, Stephen S. Gottlieb, Mitchell A. Psotka, Giuseppe M.C. Rosano et al. · 2023 · European Journal of Heart Failure
23. SGLT2-inhibitors in diabetic patients with severe aortic stenosis and cardiac damage undergoing transcatheter aortic valve implantation (TAVI)
    Pasquale Paolisso, Marta Belmonte, Emanuele Gallinoro, Roberto Scarsini, Luca Bergamaschi, Leonardo Portolan, Matteo Armillotta, Giuseppe Esposito, Elisabetta Moscarella, Giovanni Benfari et al. · 2024 · Cardiovascular Diabetology
24. Comparative Outcomes of Empagliflozin to Dapagliflozin in Patients With Heart Failure
    Katherine L. Modzelewski, Alexandra R. Pipilas, Nicholas A. Bosch · 2024 · JAMA Network Open
25. Hypertension and Heart Failure: From Pathophysiology to Treatment
    Giovanna Gallo, Carmine Savoia · 2024 · International Journal of Molecular Sciences
26. Evidence-Based Application of Natriuretic Peptides in the Evaluation of Chronic Heart Failure With Preserved Ejection Fraction in the Ambulatory Outpatient Setting
    Yogesh N.V. Reddy, Atsushi Tada, Masaru Obokata, Rickey E. Carter, David M. Kaye, M. Louis Handoko, Mads Jønsson Andersen, Kavita Sharma, Ryan James Tedford, Margaret M. Redfield et al. · 2025 · Circulation
27. Heart Failure and Cardiorenal Syndrome: A Narrative Review on Pathophysiology, Diagnostic and Therapeutic Regimens—From a Cardiologist’s View
    Angelos C. Mitsas, Mohamed Elzawawi, Sophie I. Mavrogeni, Michael Boekels, Asim Ali Khan, Mahmoud Eldawy, Ioannis Stamatakis, Dimitrios Kouris, Baraa Daboul, Oliver Gunkel et al. · 2022 · Journal of Clinical Medicine
28. Cardiovascular and Kidney Risks in Individuals With Type 2 Diabetes: Contemporary Understanding With Greater Emphasis on Excess Adiposity
    Sattar, Naveed, Presslie, Calum, Rutter, Martin K., McGuire, Darren K. · 2024 · Diabetes Care
29. Baseline Characteristics of Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF Trial
    Scott David Solomon, John W. Ostrominski, Muthiah Vaduganathan, Brian Lee Claggett, Pardeep S. Jhund, Akshay Suvas Desai, Carolyn S.P. Lam, Bertram Pitt, Michele Senni, Sanjiv Jayendra Shah et al. · 2024 · European Journal of Heart Failure
30. Prevention of cardiorenal complications in people with type 2 diabetes and obesity
    Daniel J. Drucker · 2024 · Cell Metabolism
31. Cardiovascular therapeutic targets of sodium-glucose co-transporter 2 (SGLT2) inhibitors beyond heart failure
    Matteo Armillotta, Francesco Angeli, Pasquale Paolisso, Marta Belmonte, Emanuel Raschi, Guido Di Dalmazi, Sara Amicone, Lisa Canton, Damiano Fedele, Nicole Suma et al. · 2025 · Pharmacology & Therapeutics
32. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials
    Junqueira, Daniela R., Zorzela, Liliane, Golder, Susan, Loke, Yoon, Gagnier, Joel J., Julious, Steven A., Li, Tianjing, Mayo-Wilson, Evan, Pham, Ba, Phillips, Rachel et al. · 2023 · Journal of Clinical Epidemiology
33. Discontinuation and reinitiation of SGLT-2 inhibitors and GLP-1R agonists in patients with type 2 diabetes: a nationwide study from 2013 to 2021
    Malik, Mariam Elmegaard, Falkentoft, Alexander Christian, Jensen, Jesper, Zahir, Deewa, Parveen, Saaima, Alhakak, Amna, Andersson, Charlotte, Petrie, Mark C., Sattar, Naveed, McMurray, John J.V. et al. · 2023 · The Lancet Regional Health - Europe
34. 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
    Chiadi E. Ndumele, Fátima Rodríguez, Dave L. Dixon, Sadiya S. Khan, Debabrata Mukherjee, Mandeep Singh Bajaj, Sripal Bangalore, Biykem Bozkurt, Khadijah K Breathett, Shoa L. Clarke et al. · 2026 · Circulation
35. Effect of Dapagliflozin on Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection Fraction
    Akshay Suvas Desai, Pardeep S. Jhund, Brian Lee Claggett, Muthiah Vaduganathan, Zi Michael Miao, Toru Kondo, Ebrahim Barkoudah, Abdel Brahimi, Eugene C. Connolly, Peter V. Finn et al. · 2022 · JAMA Cardiology
36. SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA
    Patrick Barry Mark, Pantelis A. Sarafidis, Robert Ekart, Charles Joseph Ferro, Olga C. Balafa, Beatriz Fernández‐Fernández, William Guy Herrington, Patrick Rossignol, Lucia Del Vecchio, José Manuel Valdivielso et al. · 2023 · Nephrology Dialysis Transplantation
37. Randomized Crossover Trial of 2-Week Ketone Ester Treatment in Patients With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction
    Nigopan Gopalasingam, Kristoffer Berg Hansen, Kristian Hylleberg Christensen, Bertil Thyrsted Ladefoged, Steen Hvitfeldt Poulsen, Mads Jønsson Andersen, Barry A. Borlaug, Roni Ranghoej Nielsen, Niels Møller, Henrik Wiggers · 2024 · Circulation
38. Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction
    Subodh Verma, Javed Butler, Barry A. Borlaug, Melanie Jane Davies, Dalane W. Kitzman, Sanjiv Jayendra Shah, Mark Colquhoun Petrie, Eric Barros, Cecilia Rönnbäck, Lene Sommer Vestergaard et al. · 2024 · Journal of the American College of Cardiology
39. Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction
    LAURA P. COHEN, Nicolás Isaza, Inmaculada Hernandez, Gregory D. Lewis, Jennifer E. Ho, Gregg C. Fonarow, Dhruv S. Kazi, Brandon Kyle Bellows · 2023 · JAMA Cardiology
40. Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction
    Javed Butler, Muhammad Usman, Gerasimos S Filippatos, João Pedro Ferreira, Michael Böhm, Martina Brueckmann, James L. Januzzi, Sanjay Kaul, Ileana L. Piña, Piotr P. Ponikowski et al. · 2023 · JAMA Cardiology
41. Recent successes in heart failure treatment
    Carolyn S.P. Lam, Kieran F. Docherty, Jennifer E. Ho, John J.V. McMurray, Peder Langeland Myhre, Torbjørn Omland · 2023 · Nature Medicine
42. Heart Failure: An Update from the Last Years and a Look at the Near Future
    Mauro Riccardi, Antonio Maria Sammartino, Massimo Francesco Piepoli, Marianna Adamo, Matteo Pagnesi, Giuseppe M.C. Rosano, Marco Metra, Stephan von Haehling, Daniela Tomasoni · 2022 · ESC Heart Failure
43. SGLT2 inhibitors reduce sudden cardiac death risk in heart failure: Meta‐analysis of randomized clinical trials
    Connor P. Oates, Carlos G. Santos‐Gallego, A. Smith, Binaya Basyal, Noah Moss, Iwanari Kawamura, Daniel Ross Musikantow, Mohit K. Turagam, Marc A. Miller, William Whang et al. · 2023 · Journal of Cardiovascular Electrophysiology
44. Guideline for the Management of Diabetes Mellitus in the Elderly in China (2024 Edition)
    Lixin Guo, Xinhua Xiao · 2024 · Aging Medicine
45. 2026 ESC Guidelines for the management of heart failure
    Lars Køber, Marianna Adamo, Anne‐Christine Ruwald, Daniela Tomasoni, Lisa Anderson, Charlotte Andersson, Jasper Jan Brugts, Ovidiu Dragomir Chioncel, Erwan Donal, Péter Ferdinandy et al. · 2026 · European Heart Journal
46. Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials
    McMurray, John J.V., Docherty, Kieran F., de Boer, Rudolf A., Hammarstedt, Ann, Kitzman, Dalane W., Kosiborod, Mikhail N., Maria Langkilde, Anna, Reicher, Barry, Senni, Michele, Shah, Sanjiv J. et al. · 2024 · Circulation
47. Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER
    Xiaowen Wang, Muthiah Vaduganathan, Brian Lee Claggett, Sheila M. Hegde, Maria A. Pabón, Ian J. Kulac, Orly Vardeny, Eileen O’Meara, Shelley R. Zieroth, Tzvetana Katova et al. · 2022 · Circulation
48. Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies
    Keong Chong, Jack. Keng-Jui Chang, Lee‐Ming Chuang · 2024 · The Kaohsiung Journal of Medical Sciences
49. Roadmap for alleviating the manifestations of ageing in the cardiovascular system
    Liberale, Luca, Tual-Chalot, Simon, Sedej, Simon, Ministrini, Stefano, Georgiopoulos, Georgios, Grunewald, Myriam, Bäck, Magnus, Bochaton-Piallat, Marie-Luce, Boon, Reinier A., Ramos, Gustavo Campos et al. · 2025 · Nature Reviews Cardiology
50. Cost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction
    Jimmy Zheng, Justin T. Parizo, John A. Spertus, Paul A. Heidenreich, Alexander T. Sandhu · 2022 · JAMA Internal Medicine
51. Management of patients with heart failure and preserved ejection fraction
    Alicja Piadlo, Patricia C. Campbell · 2023 · Heart
52. Ertugliflozin for Functional Mitral Regurgitation Associated With Heart Failure: EFFORT Trial
    Duk‐Hyun Kang, Sung‐Ji Park, Sung‐Hee Shin, In‐Chang Hwang, Yeonyee Elizabeth Yoon, Hyung‐Kwan Kim, Mijin Kim, Min‐Seok Kim, Sung‐Cheol Yun, Jong‐Min Song et al. · 2024 · Circulation
53. Combined endurance and resistance exercise training in heart failure with preserved ejection fraction: a randomized controlled trial
    Frank Edelmann, Rolf Wachter, André Duvinage, Stephan Mueller, Isabel Fegers‐Wustrow, Silja Schwarz, Jeffrey Wilcox Christle, Elisabeth Pieske‐Kraigher, Melchior Seyfarth, Markus Knapp et al. · 2025 · Nature Medicine
54. Sodium‐Glucose Cotransporter‐2 Inhibitors After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Population‐Based Investigation
    Osung Kwon, Jun‐Pyo Myong, Yunhee Lee, Yeon-Jik Choi, Jeong Eun Yi, Suk Min Seo, Sung-Won Jang, Pum Joon Kim, Jung‐Min Lee · 2023 · Journal of the American Heart Association
55. SGLT2 inhibitors: Beyond glycemic control
    Irtiza Hasan, Tasnuva Rashid, Vishal Jaikaransingh, Charles Heilig, Emaad M. Abdel‐Rahman, Alaa S. Awad · 2024 · Journal of Clinical & Translational Endocrinology
56. Dapagliflozin and Right Ventricular–Pulmonary Vascular Interaction in Heart Failure With Preserved Ejection Fraction
    Yogesh N.V. Reddy, Rickey E. Carter, Hidemi Sorimachi, Massar Omar, Dejana Popović, Alessio Alogna, Michael D. Jensen, Barry A. Borlaug · 2024 · JAMA Cardiology
57. Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid–Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout
    Jawad H. Butt, Kieran F. Docherty, Brian Lee Claggett, Akshay Suvas Desai, Magnus Petersson, Anna Maria Langkilde, Rudolf A. de Boer, Adrian F. Hernandez, Silvio E. Inzucchi, Mikhail Kosiborod et al. · 2023 · JAMA Cardiology
58. Sodium–Glucose Cotransporter-2 Inhibitors in Heart Failure: Potential Decongestive Mechanisms and Current Clinical Studies
    Jan Biegus, Marat Fudim, Husam M. Salah, Hiddo J.L. Heerspink, Adriaan A. Voors, Piotr P. Ponikowski · 2023 · European Journal of Heart Failure
59. SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
    Bartosz Rolek, Mateusz Haber, Magdalena Gajewska, Sylwester Rogula, Arkadiusz Pietrasik, Aleksandra Gąsecka · 2023 · Journal of Cardiovascular Development and Disease
60. Uncovering the Role of Epicardial Adipose Tissue in Heart Failure With Preserved Ejection Fraction
    Sarah A Goldman, Juan Antonio Requena-Ibáñez, Ana Devesa, Carlos G. Santos‐Gallego, Juan J. Badimón, Valentı́n Fuster · 2023 · JACC Advances
61. Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
    Safia Chatur, Muthiah Vaduganathan, Brian Lee Claggett, Orly Vardeny, Akshay Suvas Desai, Pardeep S. Jhund, Rudolf A. de Boer, Carolyn S.P. Lam, Mikhail Kosiborod, Sanjiv Jayendra Shah et al. · 2023 · European Heart Journal
62. Inflammageing, a targetable pathway for preventing cardiovascular diseases
    Juan Francisco Aranda, Cristina M. Ramírez, María Mittelbrunn · 2024 · Cardiovascular Research
63. Effect of Sacubitril/Valsartan vs Valsartan on Left Atrial Volume in Patients With Pre–Heart Failure With Preserved Ejection Fraction
    Mark T. Ledwidge, Jonathan Dermot Dodd, Fiona Ryan, Claire Mac Sweeney, K McDonald, Rebecca Fox, E Shorten, Shuaiwei Zhou, Chris J Watson, Joseph Gallagher et al. · 2023 · JAMA Cardiology
64. Sodium–glucose co-transporter-2 inhibitors for the prevention of atrial fibrillation: a systemic review and meta-analysis
    Hongda Zhang, Lei Ding, Lijie Mi, Ai-Kai Zhang, Kuo Zhang, Zihan Jiang, Fengyuan Yu, Xin-Xin Yan, Yu-Jing Shen, Min Tang · 2023 · European Journal of Preventive Cardiology
65. Sodium–Glucose Cotransporter 2 Inhibitors for Transthyretin Amyloid Cardiomyopathy: Analyses of Short-Term Efficacy and Safety
    Frederick Lang, Sergio Luis Teruya, Ariel Weinsaft, Margaret Cuomo, Alfonsina Mirabal Santos, Ani Nalbandian, Dimitrios Bampatsias, Mathew S. Maurer · 2024 · European Journal of Heart Failure
66. Effect of Sodium-Glucose Cotransporter 2 Inhibitors in Adults With Congenital Heart Disease
    Ralph M.L. Neijenhuis, Simon Thomas MacDonald, Filip Zemrak, Bart J.A. Mertens, Anna Dinsdale, Amanda L. Hunter, Niki L. Walker, Lorna Swan, Sushma Reddy, Joris I. Rotmans et al. · 2024 · Journal of the American College of Cardiology
67. The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF)
    Hullon, Darshan, Subeh, Ghasaq K., Volkova, Yelizaveta, Janiec, Karolina, Trach, Adam, Mnevets, Ruslan · 2025 · Cardiovascular Diabetology
68. Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
    Peder Langeland Myhre, Muthiah Vaduganathan, Brian Lee Claggett, Zi Michael Miao, Pardeep S. Jhund, Rudolf A. de Boer, Adrian F. Hernandez, Silvio E. Inzucchi, Mikhail Kosiborod, Carolyn S.P. Lam et al. · 2022 · JACC Heart Failure
69. Impact of dapagliflozin on cardiac function following anterior myocardial infarction in non-diabetic patients – DACAMI (a randomized controlled clinical trial)
    Tarek Khairy Abdeldayem, Omar Younis, Bassem Zarif, Sameh Attia, Ahmed AbdelSalam · 2023 · International Journal of Cardiology
70. Effects of empagliflozin on liver fat in patients with metabolic dysfunction–associated steatotic liver disease without diabetes mellitus: A randomized, double-blind, placebo-controlled trial
    Ka Shing Cheung, Ho Yu Ng, Rex Wan Hin Hui, Lok Ka Lam, Lung‐Yi Mak, Yuen Chi Ho, Jing Tong Tan, Esther W. Chan, Wai‐Kay Seto, Man‐Fung Yuen et al. · 2024 · Hepatology
71. The Use of Left Ventricular Ejection Fraction in the Diagnosis and Management of Heart Failure. A Clinical Consensus Statement of the Heart Failure Association (HFA) of the ESC, the Heart Failure Society of America (HFSA), and the Japanese Heart Failure Society (JHFS)
    Giuseppe M.C. Rosano, John R. Teerlink, Koichiro Kinugawa, Antoni Bayés‐Genís, Ovidiu Dragomir Chioncel, James Chen-Tson Fang, Barry Greenberg, Nasrien E. Ibrahim, Teruhiko Imamura, Takayuki Inomata et al. · 2025 · European Journal of Heart Failure
72. The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction
    Ulrich Kintscher, Frank Edelmann · 2023 · Cardiovascular Diabetology
73. Recurrent Events in Cardiovascular Trials
    John Gregson, Gregg W. Stone, Deepak L. Bhatt, Milton Packer, Stefan D. Anker, Cordula Zeller, Björn Redfors, Stuart Pocock · 2023 · Journal of the American College of Cardiology
74. Chinese Guidelines for the Diagnosis and Treatment of Heart Failure 2024
    Shu-Yang ZHANG · 2025 · 老年心脏病学杂志：英文版
75. Mechano-energetic uncoupling in heart failure
    Dunja Aksentijević, Simon Sedej, Jérémy Fauconnier, Mélanie Paillard, Mahmoud Abdellatif, Katrin Streckfuß‐Bömeke, Renée Ventura‐Clapier, Jolanda van der Velden, Rudolf A. de Boer, Edoardo Bertero et al. · 2025 · Nature Reviews Cardiology
76. Pharmacological Treatments in Heart Failure With Mildly Reduced and Preserved Ejection Fraction
    Stefanos Zafeiropoulos, Ioannis T. Farmakis, Ioannis Milioglou, Ioannis Doundoulakis, Eiran Z. Gorodeski, Stavros Konstantinides, Lauren Beth Cooper, Stavros P. Zanos, Stavros Stavrakis, Grigorios Giamouzis et al. · 2023 · JACC Heart Failure
77. Vascular (dys)function in the failing heart
    Luca Liberale, Dirk Jan Duncker, Derek John Hausenloy, Simon C Kraler, Hans Erik Bøtker, Bruno Karl Podesser, Gerd Heusch, Petra Kleinbongard · 2025 · Nature Reviews Cardiology
78. Efficacy and safety profile of SGLT2 inhibitors in the elderly: how is the benefit/risk balance?
    Scheen, André J., Bonnet, Fabrice · 2023 · Diabetes & Metabolism
79. Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Treatment
    Jong‐Chan Youn, Darae Kim, Jae Yeong Cho, Dong‐Hyuk Cho, Sang Min Park, Mi‐Hyang Jung, Junho Hyun, Hyun‐Jai Cho, Seong‐Mi Park, Jin‐Oh Choi et al. · 2023 · International Journal of Heart Failure
80. Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function
    Safia Chatur, Muthiah Vaduganathan, Brian Lee Claggett, Finnian R. Mc Causland, Akshay Suvas Desai, Pardeep S. Jhund, Rudolf A. de Boer, Adrian F. Hernandez, Silvio E. Inzucchi, Mikhail Kosiborod et al. · 2023 · Journal of the American College of Cardiology
81. Myocardial Sodium–Glucose Cotransporter 2 Expression and Cardiac Remodelling in Patients with Severe Aortic Stenosis: The BIO-AS Study
    Lucia Scisciola, Pasquale Paolisso, Marta Belmonte, Emanuele Gallinoro, Leen Delrue, Fatemeh Taktaz, Rosaria Anna Fontanella, Ivan Degrieck, Ada Pesapane, Filip P A Casselman et al. · 2024 · European Journal of Heart Failure
82. Prognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection Fraction
    Kirsty McDowell, Toru Kondo, Atefeh Talebi, Ken Teh, Erasmus Bachus, Rudolf A. de Boer, Ross T. Campbell, Brian Lee Claggett, A S Desai, Kieran F. Docherty et al. · 2024 · JAMA Cardiology
83. Cardiovascular-Kidney-Metabolic Overlap in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
    John W. Ostrominski, Brian Lee Claggett, Zi Michael Miao, Finnian R. Mc Causland, Inder S. Anand, Akshay Suvas Desai, Pardeep S. Jhund, Carolyn S.P. Lam, Marc Alan Pfeffer, Bertram Pitt et al. · 2024 · Journal of the American College of Cardiology
84. Tadalafil for Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction: A Randomized Controlled Phase 3 Study
    Marius M. Hoeper, Britta Oerke, Max Wißmüller, Hanno H. Leuchte, Christian F. Opitz, Michael Halank, Hans-Juergen Seyfarth, Stephan Ernst Baldus, Johann K Bauersachs, Michael Böhm et al. · 2024 · Circulation
85. Endothelial Protection by Sodium-Glucose Cotransporter 2 Inhibitors: A Literature Review of In Vitro and In Vivo Studies
    Nikolaos Mylonas, Panagiota Nikolaou, Paschalis Karakasis, Panagiotis Stachteas, Nikolaos Fragakis, Ioanna Andreadou · 2024 · International Journal of Molecular Sciences
86. Clinical Updates in Coronary Artery Disease: A Comprehensive Review
    Andrea Bottardi, Guy F. A. Prado, Mattia Lunardi, Simone Fezzi, Gabriele Pesarini, Domenico Tavella, Roberto Scarsini, Flavio Luciano Ribichini · 2024 · Journal of Clinical Medicine
87. Obesity, Heart Failure with Preserved Ejection Fraction, and the Role of Glucagon-Like Peptide-1 Receptor Agonists
    Giuliana Cimino, Muthiah Vaduganathan, Carlo Lombardi, Matteo Pagnesi, Enrico Vizzardi, Daniela Tomasoni, Marianna Adamo, Marco Metra, Riccardo Maria Inciardi · 2023 · ESC Heart Failure
88. Prescription Patterns for Sodium-Glucose Cotransporter 2 Inhibitors in U.S. Health Systems
    Jung‐Im Shin, Yunwen Xu, Alex R. Chang, Juan Jesús Carrero, Carina M. Flaherty, Amrita Mukhopadhyay, Lesley A. Inker, Saul Blecker, Leora Idit Horwitz, Morgan Erika Grams · 2024 · Journal of the American College of Cardiology
89. Natriuretic Peptides, Kidney Function, and Clinical Outcomes in Heart Failure With Preserved Ejection Fraction
    Brendon Lange Neuen, Muthiah Vaduganathan, Brian Lee Claggett, Iris E. Beldhuis, Peder Langeland Myhre, Akshay Suvas Desai, Hicham Skali, Finnian R. Mc Causland, Martina M. McGrath, Inder S. Anand et al. · 2024 · JACC Heart Failure
90. Finerenone in Patients With a Recent Worsening Heart Failure Event
    Akshay Suvas Desai, Muthiah Vaduganathan, Brian Lee Claggett, Ian J. Kulac, Pardeep S. Jhund, Jonathan W. Cunningham, Maria Borentain, James Lay‐Flurrie, Prabhakar Viswanathan, Katja Rohwedder et al. · 2024 · Journal of the American College of Cardiology
91. Left ventricular hypertrophy and myocardial fibrosis in heart failure with preserved ejection fraction: mechanisms and treatment
    Alexander Peikert, Marianna Fontana, Scott David Solomon, Thomas Thum · 2025 · European Heart Journal
92. Impact of SGLT2 Inhibitor Therapy on Right Ventricular Function in Patients with Heart Failure and Reduced Ejection Fraction
    Ivona Mustapić, Darija Baković, Zora Sušilović Grabovac, Josip A. Borovac · 2022 · Journal of Clinical Medicine
93. Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF
    Alexander Peikert, Bradley A. Bart, Muthiah Vaduganathan, Brian Lee Claggett, Ian J. Kulac, Mikhail Kosiborod, Akshay Suvas Desai, Pardeep S. Jhund, Carolyn S.P. Lam, Silvio E. Inzucchi et al. · 2023 · JACC Heart Failure
94. Clinical Recommendations for Managing Genitourinary Adverse Effects in Patients Treated with SGLT-2 Inhibitors: A Multidisciplinary Expert Consensus
    Juan José Gorgojo Martínez, José Luis Górriz, Ana María Cebrián Cuenca, Almudena Castro Conde, María Velasco · 2024 · Journal of Clinical Medicine
95. Prevalence, Characteristics, Management and Outcomes of Patients with Heart Failure with Preserved, Mildly Reduced, and Reduced Ejection Fraction in Spain
    Carlos Escobar, Beatriz Palacios, Luis F. Varela, Martín Gutiérrez, Mai Duong, Hungta Chen, Nahila Justo, Javier Cid-Ruzafa, Ignacio Hernández, Phillip R. Hunt et al. · 2022 · Journal of Clinical Medicine
96. Heart Failure With Preserved Ejection Fraction With CKD: A Narrative Review of a Multispecialty Disorder
    Rahul Patel, Akash Sharma, Anand Prasad, Shweta Bansal · 2023 · Kidney Medicine
97. Heart failure management guidelines: New recommendations and implementation
    Paul A. Heidenreich · 2023 · Journal of Cardiology
98. Lipotoxicity as a therapeutic target in obesity and diabetic cardiomyopathy
    Michinari Nakamura · 2024 · Journal of Pharmacy & Pharmaceutical Sciences
99. Cardiometabolic and renal benefits of sodium–glucose cotransporter 2 inhibitors
    Yong‐ho Lee, Soo Kyung Lim, Melanie Jane Davies · 2025 · Nature Reviews Endocrinology
100. Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction
     Jawad H. Butt, Toru Kondo, Pardeep S. Jhund, Josep Comin Colet, Rudolf A. de Boer, Akshay Suvas Desai, Adrian F. Hernandez, Silvio E. Inzucchi, Stefan P. Janssens, Mikhail Kosiborod et al. · 2022 · Journal of the American College of Cardiology